Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer

NCT06705686 is registered in ClinicalTrials.gov with TechnoGenesys, Inc. as lead sponsor.

NCT NCT06705686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06705686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer
Lead sponsor
TechnoGenesys, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 13, 2026
Completion date
March 30, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer (crpc), metastatic castration-resistant prostate carcinoma